SEC Company Response from OKYO Pharma (OKYO) — Feb 6, 2026
OKYO Pharma Ltd
Date: Feb. 6, 2026 · CIK: 0001849296 · Accession: 0001493152-26-005639
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293145
Letter
OKYO Pharma LTD.
Martello Court
Admiral Park
St. Peter Port
Guernsey GY1 3HB
VIA EDGAR
February 6, 2026
Securities and Exchange Commission
Division of Investment Management
100 F Street, N.E.
Washington, D.C. 20549
Re: OKYO Pharma Ltd.
Registration Statement on Form F-3
Filed February 2, 2026
SEC File No. 333-293145
To Whom It May Concern:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, OKYO Pharma Ltd. (the "Registrant") hereby requests that the effective date of the above-referenced Registration Statement (the "Registration Statement") be accelerated so that the Registration Statement may become effective no earlier than 9:00 a.m., Eastern Time, on February 10, 2026, or as soon as practicable thereafter.
The Registrant requests that notification of such effectiveness be made by telephone call to Anna Tomczyk of Dechert LLP, legal counsel to the Registrant, at 212-641-5626.
Very truly yours,
OKYO PHARMA LTD.
Show Raw Text
CORRESP 1 filename1.htm OKYO Pharma LTD. Martello Court Admiral Park St. Peter Port Guernsey GY1 3HB VIA EDGAR February 6, 2026 Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, D.C. 20549 Re: OKYO Pharma Ltd. Registration Statement on Form F-3 Filed February 2, 2026 SEC File No. 333-293145 To Whom It May Concern: Pursuant to Rule 461 under the Securities Act of 1933, as amended, OKYO Pharma Ltd. (the "Registrant") hereby requests that the effective date of the above-referenced Registration Statement (the "Registration Statement") be accelerated so that the Registration Statement may become effective no earlier than 9:00 a.m., Eastern Time, on February 10, 2026, or as soon as practicable thereafter. The Registrant requests that notification of such effectiveness be made by telephone call to Anna Tomczyk of Dechert LLP, legal counsel to the Registrant, at 212-641-5626. Very truly yours, OKYO PHARMA LTD. By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer